Announcements
- Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
- Belite Bio Announces $25 Million Registered Direct Offering
- Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
- Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
- Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
- Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
- Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
- Belite Bio to Participate in the BTIG Ophthalmology Day
More ▼
Key statistics
52-week range
Open | 39.40 |
---|---|
High | 39.40 |
Low | 39.40 |
Bid | 39.40 |
Offer | 41.00 |
Previous close | 37.60 |
Average volume | 0.00 |
---|---|
Shares outstanding | 29.75m |
Free float | 11.38m |
P/E (TTM) | -- |
Market cap | 1.29bn USD |
EPS (TTM) | -1.24 USD |
Data delayed at least 15 minutes, as of May 06 2024 07:13 BST.
More ▼